by Takeda UK
with support from Makara Health
by Takeda
with support from Edelman
by CSL Behring
with support from Pegasus
by Galderma
with support from Havas Life Medicom
by Norgine
with support from earthware
by Norgine
with support from earthware
In Europe, 200,000 people are affected by Hepatic encephalopathy (HE) – a potentially fatal decline in brain function as a result of liver disease. HE is preventable and treatable, yet poorly diagnosed as many patients and carers are unaware of the signs and symptoms of the disease.
LiverSync® is a free, software-based, class 1 medical device (under Medical Device Directives, or MDD) developed by Norgine and earthware. It is designed to help liver disease patients living with liver cirrhosis who have had, or are at high risk of developing, HE.
Using a range of short cognitive tests that patients can complete anytime, anywhere, the LiverSync® app monitors trends in brain function and memory that may be affected by advanced liver disease. Patients can share information from the app with carers and healthcare professionals, helping them to get a diagnosis and treatment as early as possible.
Delivered in four languages, in a time frame of just ten months, LiverSync® is the first, comprehensive patient app and HCP web platform that allows patients, carers and HCPs to test and track patients’ cognition in real time and over time, to allow rapid interventions and active management of HE symptoms as they develop.
The judges enjoyed this entry and the app. Norgine and earthware did really well to develop it in such a short period of time and it is a great tool for patients to identify with and was very ambitious launching in several countries.
Entry deadline | 27 August 2020 |
Extended entry deadline | 3 September 2020* *additional fee applies |
Judging Day | 1 October 2020 |
Company of the Year Interviews | 22 October 2020 |
PMEA Event | 25 November 2020 |